BBOT · BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics executed a comprehensive leadership transition on April 20-21, 2026, involving the appointment of three C-suite officers and the departure of the former CEO and CFO. Pedro Beltran, Ph.D., the former Chief Scientific Officer, was appointed President and CEO, succeeding founder Eli Wallace, Ph.D. Dr. Wallace resigned from the Board and executive role without disagreement but will remain as a senior advisor, ensuring continuity of scientific strategy. Concurrently, Idan Elmelech was promoted to Chief Operating Officer from his role as SVP of Strategy and Business Development. The transition extends to the finance function, where CFO Uneek Mehra departed effective April 21, 2026. Mr. Elmelech assumed the additional role of Principal Financial Officer, while Marc Cobo, the Vice President of Finance and Controller, was appointed Principal Accounting Officer. Additionally, Neil Kumar, Ph.D., was appointed Executive Chairman. The Board indicated these changes are designed to accelerate and focus the development of BBOT's programs as the company enters Phase 1b expansions across multiple RAS-driven cancers. Compensation for the new executives includes standard at-will employment terms with base salaries, target bonuses, and equity eligibility, with Dr. Beltran receiving Tier 1 severance benefits and Mr. Elmelech receiving Tier 2 severance benefits.